The Fight Against COVID19

Stock market news live updates: Stock futures open flat after regular session drop

Stock futures were little changed Tuesday evening, struggling for direction after equities sputtered into the close earlier in the day.

Why Inovio Stock Soared 83% in June

What happened Inovio Pharmaceuticals (NASDAQ: INO) stock skyrocketed 82.7% in June, according to data from S&P Global Market Intelligence. The S&P 500 returned 2% last month. In July, shares of the coronavirus vaccine developer, however, have given back a chunk of last month's gain: Through Tuesday, July 7, they're down nearly 11%, while the broader market has returned just over 3%.

• 
  Analyst Sounds the Valuation Alarm Bell on Inovio’s Hot Stock

  TipRanks
• 
  After months of speculation, investors get excited about Pfizer, BioNTech’s coronavirus vaccine candidate

  MarketWatch

Regeneron Initiates Studies on Experimental Coronavirus Drug

Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

Report: Moderna and Feds Fight Over Coronavirus Vaccine Clinical Trials

The two sides are apparently arguing over several issues, including protocols and information sharing.

• 
  Moderna’s COVID-19 Trial Delayed: Should Investors Worry?

  Motley Fool
• 
  Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials

  Reuters

GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact

GlaxoSmithKline (NYSE: GSK) announced Tuesday that Medicago -- a private company owned by Mitsubishi Tanabe Pharma (OTC: MTZXF) and Philip Morris International (NYSE: PM) -- will use GlaxoSmithKline's adjuvant in a COVID-19 vaccine it expects to enter phase 1 trials this month. Medicago's recombinant coronavirus "Virus-Like Particles" will be combined with Glaxo's pandemic adjuvant system to boost immune response, potentially allowing for less antigen per dose and thus, more available vaccine doses.

• 
  GSK to develop plant-based COVID-19 vaccine with Canada's Medicago

  Reuters
• 
  Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal: report

  Reuters

Johnson & Johnson (JNJ) Stock Moves -0.09%: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $142.85, marking a -0.09% move from the previous day.

• 
  Advanced Micro Devices (AMD) Stock Moves -0.88%: What You Should Know

  Zacks
• 
  Gilead Sciences (GILD) Stock Moves -0.44%: What You Should Know

  Zacks

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

Pfizer (PFE) closed the most recent trading day at $34.03, moving -1.39% from the previous trading session.

• 
  Gilead Sciences (GILD) Stock Moves -0.44%: What You Should Know

  Zacks
• 
  Salesforce.com (CRM) Stock Moves -0.68%: What You Should Know

  Zacks

Gilead Sciences (GILD) Stock Moves -0.44%: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.

• 
  Advanced Micro Devices (AMD) Stock Moves -0.88%: What You Should Know

  Zacks
• 
  Salesforce.com (CRM) Stock Moves -0.68%: What You Should Know

  Zacks

The Stock Market Is Bouncing as Biotechs Climb on Coronavirus Vaccine Deals

Efforts to find treatments for the COVID-19 pandemic have taken top priority at many companies in the space, and today, Novavax (NASDAQ: NVAX) and Regeneron Pharmaceuticals (NASDAQ: REGN) got good news from the federal government. Novavax shares were up more than 30% Tuesday morning as investors reacted positively to the latest news from the biotech. As a major player in the race to find a coronavirus vaccine, Novavax got a shot in the arm from the Department of Health and Human Services.

• 
  Novavax Spikes 42% Pre-Market On $1.6B U.S. Funding For Covid-19 Candidate

  SmarterAnalyst
• 
  Coronavirus update: US moves to end WHO membership; Brazil's Bolsonaro tests positive

  Yahoo Finance

Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine

Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.

• Catalent plant in Italy will help produce J&J's potential COVID-19 vaccine: minister

  Reuters
• Emergent BioSolutions inks coronavirus vaccine manufacturing deal with J&J

  MarketWatch

Top Ranked Value Stocks to Buy for July 7th

Top Ranked Value Stocks to Buy for July 7th

• 
  New Strong Buy Stocks for July 6th

  Zacks
• 
  Top Ranked Income Stocks to Buy for July 6th

  Zacks

Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis

Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.

Novavax Awarded $1.6 Billion From Operation Warp Speed to Fund COVID-19 Vaccine Program

The funds will support the rapid development and mass production of the biotech's coronavirus vaccine candidate, NVX-CoV2373.

• 
  Novavax Spikes 42% Pre-Market On $1.6B U.S. Funding For Covid-19 Candidate

  SmarterAnalyst
• 
  Coronavirus update: US moves to end WHO membership; Brazil's Bolsonaro tests positive

  Yahoo Finance

Better Coronavirus Stock: Moderna vs. Sorrento Therapeutics

As a result, investors have begun panic-buying biotech companies on the frontiers of creating new treatments and vaccines for COVID-19. In another article, I discussed how the company made some glaring statements regarding the effectiveness of its antibodies on Fox News. Here, we will focus on what Sorrento is doing in other significant areas to fight the pandemic.

Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners

Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners

• 
  Top Stock Reports for Alibaba, NVIDIA & Bristol Myers Squibb

  Zacks
• 
  Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

  Zacks

Company News for Jul 7, 2020

Companies in The News Are: BRK.B, D, UBER, REGN, SINA.

• 
  Stock Market News for Jul 6, 2020

  Zacks
• 
  'Wall Street is almost always late to the party': Expert

  Yahoo Finance Video

Here's the Surprising Coronavirus Stock You'll Really Want to Own

A "black swan" event is a highly unusual, utterly unpredictable happening that throws everybody for a loop. As far as the stock market is concerned, black swans are almost always bad. For instance, 9/11 was a black swan.

Why Novavax Stock Is Skyrocketing Today

Novavax lands a massive $1.6 billion award from the federal government's Operation Warp Speed program.

• 
  Novavax Spikes 42% Pre-Market On $1.6B U.S. Funding For Covid-19 Candidate

  SmarterAnalyst
• 
  Coronavirus update: US moves to end WHO membership; Brazil's Bolsonaro tests positive

  Yahoo Finance

4 Value Stocks to Buy in a Recovering Economy

Vitals of financial markets and the U.S. economy are recovering gradually, making way for value stocks to gain pace ahead.

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

Moderna’s COVID-19 Trial Delayed: Should Investors Worry?

Moderna (NASDAQ: MRNA) was one of the first companies to kick off a phase 1 clinical trial for its investigational COVID-19 vaccine, mRNA-1273. The trial tested the vaccine's safety, immunogenicity (ability to cause immune system response), and reactogenicity (possible side effects). After getting the green light from the U.S. Food and Drug Administration (FDA), Moderna started a phase 2 trial for mRNA-1273 in May. This trial will test the safety, immunogenicity, and reactogenicity of the vaccine in a pool of 600 healthy participants.

• 
  Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials

  Reuters
• 
  Report: Moderna and Feds Fight Over Coronavirus Vaccine Clinical Trials

  Motley Fool

Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials

The federal government is supporting Moderna’s vaccine project with nearly half a billion dollars and has chosen it as one of the first to enter large-scale human trials. The sources said those tensions, which have not been previously reported, have contributed to a delay of more than two weeks in launching the trial of the Moderna’s vaccine candidate, now expected in late July.

• 
  Moderna’s COVID-19 Trial Delayed: Should Investors Worry?

  Motley Fool
• 
  Report: Moderna and Feds Fight Over Coronavirus Vaccine Clinical Trials

  Motley Fool

Dow Jones Futures: Coronavirus Stock Market Rally Steps Back, But Tesla, These Leaders Advance; Facebook In Focus Late

The stock market rally had a down day, but not hot EV plays Tesla and Nio. Facebook is in focus late after Mark Zuckerberg met with ad boycott organizers.